Date: 2011-10-24
Type of information: R&D agreement
Compound: novel microRNAs candidate drugs based on AtuPLEX™ and DBTC delivery systems
Company: Silence Therapeutics (UK) Mirna Therapeutics (USA)
Therapeutic area:
Type agreement: R&D
collaboration
Action mechanism: Silence’s proprietary lipid delivery technology AtuPLEX™ has demonstrated the broad systemic delivery to the vascular endothelium. Formulations generated with the AtuPLEX™ technology can be lyophilized (freeze dried) significantly improving stability, shipping and handling.
Disease: undisclosed
Details: Silence Therapeutics has entered into an agreement with Mirna Therapeutics, a biopharmaceutical company pioneering microRNA-based therapeutics for cancer, to assess the delivery capabilities of Silence’s proprietary AtuPLEX™ and DBTC delivery systems for Mirna’s novel microRNAs.
Under the terms of the agreement, Mirna will provide Silence with specific miRNA sequences, which Silence will formulate with its AtuPLEX™ and DBTC delivery systems in order to develop multiple candidate drugs. Mirna will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation.
Financial terms: Financial terms of the deal were not disclosed.
Latest news:
